Online citations, reference lists, and bibliographies.
← Back to Search

Enhancement Of Oral Bioavailability Of Pentoxifylline By Solid Lipid Nanoparticles

J. Varshosaz, M. Minayian, Elaheh Moazen
Published 2010 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Pentoxifylline (PTX) is a highly water-soluble, hemorheologic drug that undergoes first-pass effect with 20% bioavailability. The solid lipid nanoparticles (SLNs) of PTX were prepared to enhance its oral bioavailability by homogenization, followed by the sonification method. Seven different variables, each at two levels, were studied: lipid type, surfactant type and concentration, speed of homogenizer, acetone:dichloromethane (DCM) ratio, lecithin:lipid ratio, and sonication time. The mean particle size and size distribution, drug entrapment efficiency (EE%), zeta potential, and drug release of the SLNs were investigated. A pharmacokinetic study was conducted in male Wistar rats after oral administration of 10 mg kg−1 PTX in the form of free drug or SLNs. The z-average particle size, zeta potential, and EE% of the SLNs were at least 250 nm, −30.2 mV, and 70%, respectively. Among the studied factors, the lipid type, surfactant type, and percentage had a significant effect on the particle size. Zeta potential was more affected by lipid type, acetone:DCM ratio, and sonication time. Speed of homogenizer and acetone:DCM ratio had a significant effect on the EE%. The optimized SLN was prepared by 80 mg of cetyl alcohol, 10 mg of lecithin, acetone:DCM ratio (1:2), 30-second sonication, 3% Tween 20, and a mixing rate of 800 rpm. In vitro drug release lasted for about 5 hours. It was found that the relative bioavailability of PTX in SLNs was significantly increased, compared to that of the PTX solution. SLNs offer a promising approach to improve the oral bioavailability of PTX that is affected by a high first-pass effect.
This paper references
10.1002/j.1552-4604.1992.tb03811.x
Comparison of Pentoxifylline Pharmacokinetics Between Smokers and Nonsmokers
V. Mauro (1992)
10.1016/j.nano.2008.08.003
Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.
Rishi Paliwal (2009)
Pentoxyphylline and propentophylline are inhibitors of TNF-alpha release in Meiners I, monocytes activated by advanced glycation endproducts
S. Hauschildt (2004)
10.1080/03639040500519367
Effect of Excipient and Processing Variables on Adhesive Properties and Release Profile of Pentoxifylline From Mucoadhesive Tablets
Madhu S. Surapaneni (2006)
10.1016/S0939-6411(97)00150-1
Solid lipid nanoparticles (SLN) for controlled drug delivery--drug release and release mechanism.
A. Zur Mühlen (1998)
10.1007/s00702-003-0066-y
Pentoxyphylline and propentophylline are inhibitors of TNF-α release in monocytes activated by advanced glycation endproducts
Ina Meiners (2004)
10.1080/00401706.1996.10484511
Engineering Methods for Robust Product Design
Henry W. Altland (1996)
10.1023/A:1018888927852
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Shicheng Yang (2004)
10.1002/JPS.10368
Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin.
R. Cavalli (2003)
10.1016/j.ijpharm.2007.12.034
Some considerations about the hydrophilic-lipophilic balance system.
R. Pasquali (2008)
10.1016/j.ijpharm.2008.10.003
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products.
J. Pardeike (2009)
Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects.
I. Raz (1988)
10.1211/jpp.58.6.0011
Examination of the impact of a range of Pluronic surfactants on the in‐vitro solubilisation behaviour and oral bioavailability of lipidic formulations of atovaquone
L. Sek (2006)
10.1016/S0168-1656(02)00179-7
Applying the Taguchi robust design to the optimization of the asymmetric reduction of ethyl 4-chloro acetoacetate by bakers' yeast.
J. Y. Houng (2003)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1023/A:1013037927882
Comparison of the Lymphatic Transport of Halofantrine Administered in Disperse Systems Containing Three Different Unsaturated Fatty Acids
R. Holm (2004)
10.1016/S0169-409X(96)00494-2
Lipid-based vehicles for the oral delivery of poorly water soluble drugs
A. Humberstone (1997)
Medication vehicles made of solid lipid particles (solid lipid nanospheres sln)
룩크스 스테판 (1992)
10.1021/JP072876Z
Evaluation of surface charge density and surface potential by electrophoretic mobility for solid lipid nanoparticles and human brain-microvascular endothelial cells.
Y. Kuo (2007)
10.1080/02652040500162378
A novel approach based on lipid nanoparticles (SLN®) for topical delivery of α-lipoic acid
E. Souto (2005)
10.1211/0022357044959
Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs
L. Hu (2004)
10.1016/S0360-3016(03)01444-5
Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial.
B. Ozturk (2004)
10.1111/j.1572-0241.1998.00699.x
Modulation of intravariceal pressure with pentoxifylline: a possible new approach in the treatment of portal hypertension
E. Eleftheriadis (1998)
10.1016/J.ADDR.2007.05.002
PrefaceLipid nanoparticles: recent advances☆
R. Mueller (2007)
Engineering Methods for Robust Product Design: Using Taguchi Methods in Technology and Product Development
W. Y. Fowlkes (1995)
10.1016/J.COLSURFB.2007.03.002
Studies on oral absorption of stearic acid SLN by a novel fluorometric method.
H. Yuan (2007)
10.1016/j.ijpharm.2008.04.045
Brain and muscle of Wistar rats are the main targets of intravenous dendrimeric sulfadiazine.
M. J. Prieto (2008)
10.1016/j.jconrel.2008.08.021
Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug.
T. Nassar (2009)
10.1016/j.ijpharm.2006.11.004
Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
V. V. Kumar (2007)
10.1016/J.JCONREL.2006.05.010
Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability.
Yifan Luo (2006)
Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles.
Li Yang (2009)
10.1080/02652040010018056
Production of solid lipid nanoparticles (SLN): scaling up feasibilities
A. Dingler (2002)
Solid lipid nanoparticles (SLNs) for controlled drug delivery—a review of the state of the art
R. H. Müller (2000)
10.1016/S0021-9797(03)00142-5
Zeta-potential measurement using the Smoluchowski equation and the slope of the current-time relationship in electroosmotic flow.
A. Sze (2003)
10.3109/10837450903013568
Production and optimization of valproic acid nanostructured lipid carriers by the Taguchi design
J. Varshosaz (2010)
10.1016/0168-3659(94)90047-7
Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization
C. Schwarz (1994)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.1016/0169-409X(95)00048-C
The importance of gastrointestinal uptake of particles in the design of oral delivery systems
E. Lavelle (1995)
Enhanced oral bioavailability of salvianolic acid B by phospholipid complex loaded nanoparticles.
Q. Peng (2008)
10.1016/S0928-0987(02)00241-5
The influence of lipid nanocapsule composition on their size distribution.
B. Heurtault (2003)
10.1016/j.ccl.2007.12.004
Antithrombotic therapy in peripheral arterial disease.
E. Lipsitz (2008)
10.2165/00003495-200464150-00004
Drug Treatment of Intermittent Claudication
Douglas S Jacoby (2012)



This paper is referenced by
10.1016/j.colsurfb.2019.05.074
Colloidal nanostructured lipid carriers of pentoxifylline produced by microwave irradiation ameliorates imiquimod-induced psoriasis in mice.
V. Ghate (2019)
10.1016/B978-0-12-800351-0.00013-4
Emerging product formation
S. Jafari (2015)
10.2174/2210681208666180321144536
Solid lipid nanoparticles: A potential approach for drug delivery system
B. Sarangi (2019)
10.1208/s12249-018-1283-x
Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study
Abd El-Halim I. El Assasy (2019)
10.22377/ajp.v12i04.2902
Solid Lipid-based Delivery System for Oral Delivery of Drugs: A Review
C. N. Patra (2019)
10.1080/09205063.2015.1061351
Effect of squalane on mebendazole-loaded Compritol® nanoparticles
R. Graves (2015)
Solid Lipid Nanoparticles – A Promising Drug Delivery System
Hristo L Svilenov (2015)
10.1007/s11095-010-0130-x
Phospholipids and Lipid-Based Formulations in Oral Drug Delivery
G. Fricker (2010)
10.1016/j.ejps.2012.05.010
Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
S. Das (2012)
Solid Lipid Nanoparticle: A Novel Drug Delivery in Pharmaceutical Science
A. Srivastava (2020)
10.1016/j.colsurfb.2012.04.027
Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
S. Chalikwar (2012)
10.3109/10837450.2013.819011
Novel lectin-modified poly(ethylene-co-vinyl acetate) mucoadhesive nanoparticles of carvedilol: preparation and in vitro optimization using a two-level factorial design
J. Varshosaz (2014)
Formulation, gastrointestinal transit studies and absorption of amphotericin B-containing solid lipid nanoparticles in rats
Hilda Amekyeh (2016)
10.1007/978-3-030-17061-5_19
Application of Nanotechnology in Diagnosis, Drug Dissolution, Drug Discovery, and Drug Carrier
Abhishek Kumar Mishra (2019)
10.1016/J.JDDST.2016.03.009
A novel cationic nanostructured lipid carrier for improvement of ocular bioavailability: Design, optimization, in vitro and in vivo evaluation
R. Liu (2016)
10.1093/milmed/usy368
Improving Relative Bioavailability of Oral Imidazolidinedione by Reducing Particle Size Using Homogenization and Ultra-Sonication.
Q. Zeng (2019)
10.1002/9783527800681.CH24
Nanodrugs in Medicine and Healthcare: Oral Delivery
A. Sosnik (2016)
Studies concerning the development of lipid nanostructures in bioproducts encapsulation.
C. Dinu-Pîrvu (2012)
10.1016/J.TIFS.2011.08.003
Nanoencapsulation of food ingredients using lipid based delivery systems
Milad Fathi (2012)
10.1208/s12249-010-9563-0
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
S. Das (2010)
10.3109/10717544.2014.923062
Formulation in vitro and in vivo evaluation of SRMS-based heterolipid-templated homolipid delivery system for diclofenac sodium
Momoh A. Mumuni (2016)
10.1016/j.chemphyslip.2012.01.007
Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds.
Anna Elgart (2012)
10.2174/2211738507666190802140607
Solid Lipid Nanoparticles of Dronedarone Hydrochloride for Oral Delivery: Optimization, In Vivo Pharmacokinetics and Uptake Studies.
V. M. Gambhire (2019)
10.1142/9781783267231_0014
Advances in Smart Nanopreparations for Oral Drug Delivery
G. A. Islan (2016)
10.1016/j.colsurfb.2013.01.011
A novel biocompatible bicephalous dianionic surfactant from oleic acid for solid lipid nanoparticles.
Rahul S. Kalhapure (2013)
10.1007/s40199-018-0209-1
Lipid-drug conjugates: a potential nanocarrier system for oral drug delivery applications
S. Banerjee (2018)
10.1002/9781119227625.CH8
Encapsulation technologies for resveratrol in functional food
M. Chávarri (2017)
Nanoencapsulation in the food industry: manufacture, applications and characterization
Alejandro J. Paredes (2016)
10.1016/j.cis.2019.06.005
Ultrasound-assisted preparation of different nanocarriers loaded with food bioactive ingredients.
Roya Koshani (2019)
10.1186/s11671-016-1471-0
Liquid Crystalline Nanoparticles as an Ophthalmic Delivery System for Tetrandrine: Development, Characterization, and In Vitro and In Vivo Evaluation
R. Liu (2016)
10.1007/s40005-013-0087-y
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery
G. Yoon (2013)
10.1080/17425255.2019.1621289
Solid lipid matrix mediated nanoarchitectonics for improved oral bioavailability of drugs
S. Banerjee (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar